Nanobiotix

Nanobiotix Expands Oncology Pipeline With $100M Funding

Paris, France and Cambridge, Massachusetts, USA, May 22, 2026 Nanobiotix, a late-stage clinical biotechnology company specializing in physics-based cancer...

By cGxPwire Editor
May 26, 2026

.Clinical

Nanobiotix Updates Phase 3 NANORAY-312 Protocol

PARIS, France and CAMBRIDGE, Mass., United States – May 4, 2026 Nanobiotix has announced FDA acceptance of a protocol...

By cGxPwire Editor
May 5, 2026

Bio-Pharma Pharma

Nanobiotix Reports Nanoprimer Breakthrough at AACR 2026

PARIS, France & CAMBRIDGE, USA, April 20, 2026 Nanobiotix has unveiled promising preclinical data demonstrating that its Nanoprimer technology...

By cGxPwire Editor
April 20, 2026

Bio-Pharma

Nanobiotix to Present at Major U.S. Healthcare Events

Nanobiotix S.A. (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches for cancer and other serious...